SCLERODERMA CLINICAL TRIALS CONSORTIUM INC (EIN 043543489) - Form 990 Financial Analysis & Trantor Score

🔒

Tuckman-Chang Vulnerability Assessment

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2001

Legal Domicile

Principal Officer

ROBYN THERESE DOMSIC-DEGAZIO

Phone

8015484837

Tax Period

2024-01-01 to 2024-12-31

SCLERODERMA CLINICAL TRIALS CONSORTIUM INC, founded in 2001, is a community nonprofit in the Medical Research sector that reported $1.2M in total revenue in fiscal year 2018. Revenue surged 694% from the prior year, signaling strong growth momentum. The organization ran a surplus of $1.1M, a strong 94% operating margin.

Mission

TO FOSTER SCIENTIFIC RESEARCH AND TO ADVANCE MEDICAL RESEARCH IN THE FORM OF TREATMENT TRIALS IN SCLERODERMA ON A WORLDWIDE BASIS.

🔒

Trantor Score

Financial Health & Payment Capacity Assessment (FICO Scale: 300–850)

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $217,229

Program Service Revenue $0

Investment Income $109,204

Other Revenue $0

TOTAL REVENUE $326,433

Expense Breakdown

Grants Paid $222,300

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $286,656

Other Expenses $76,302

TOTAL EXPENSES $298,602

Year-over-Year Comparison

	2024	2023	Change
Revenue	$326,433	$264,484	+0.2%
Expenses	$298,602	$210,242	+0.4%
Net Income	$27,831	$54,242	-0.5%

Key Indicators

✗ Grants to Organizations ✓ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
ROBYN THERESE DOMSIC-DEGAZIO	PRESIDENT	N/A	Officer	$0	$0	$0
TRACY FRENCH	VICE PRESIDE	N/A	Officer	$0	$0	$0
JERRY A MOLITOR	TREASURER	N/A	Officer	$0	$0	$0
VANESSA SMITH	SECRETARY	N/A	Officer	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$326,433	$298,602	$4,030,611	$27,831
2023	$264,484	$210,242	$3,466,894	$54,242
2022	$271,981	$177,441	$2,536,410	$94,540
2021	$197,214	$95,927	$2,441,870	$101,287
2020	$222,811	$168,700	$2,340,583	$54,111
2019	$1,210,041	$126,858	$2,286,472	$1,083,183
2018	$1,187,078	$76,552	$1,203,289	$1,110,526

SCLERODERMA CLINICAL TRIALS CONSORTIUM INC